{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:51:14Z","timestamp":1774612274025,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["PP00P3_170702"],"award-info":[{"award-number":["PP00P3_170702"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The only licensed malaria vaccine, RTS,S\/AS01, has been developed for morbidity-control in young children. The potential impact on transmission of deploying such anti-infective vaccines to wider age ranges, possibly with co-administration of antimalarial treatment, is unknown. Combinations of existing malaria interventions is becoming increasingly important as evidence mounts that progress on reducing malaria incidence is stalling and threatened by resistance.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Malaria transmission and intervention dynamics were simulated using <jats:italic>OpenMalaria,<\/jats:italic> an individual-based simulation model of malaria transmission, by considering a seasonal transmission setting and by varying epidemiological and setting parameters such as transmission intensity, case management, intervention types and intervention coverages. Chemopreventive drugs and anti-infective vaccine efficacy profiles were based on previous studies in which model parameters were fitted to clinical trial data. These intervention properties were used to evaluate the potential of seasonal mass applications of preventative anti-infective malaria vaccines, alone or in combination with chemoprevention, to reduce malaria transmission, prevent resurgence, and\/or reach transmission interruption.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Deploying a vaccine to all ages on its own is a less effective intervention strategy compared to chemoprevention alone. However, vaccines combined with drugs are likely to achieve dramatic prevalence reductions and in few settings, transmission interruption. The combined mass intervention will result in lower prevalence following the intervention compared to chemoprevention alone and will increase chances of interruption of transmission resulting from a synergistic effect between both interventions. The combination of vaccine and drug increases the time before transmission resurges after mass interventions cease compared to mass treatment alone. Deploying vaccines and drugs together requires fewer rounds of mass intervention and fewer years of intervention to achieve the same public health impact as chemoprevention alone.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Through simulations we identified a previously unidentified value of deploying vaccines with drugs, namely the greatest benefit will be in preventing and delaying transmission resurgence for longer periods than with other human targeted interventions. This is suggesting a potential role for deploying vaccines alongside drugs in transmission foci as part of surveillance-response strategies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-019-4467-4","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T20:44:43Z","timestamp":1572468283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Mass campaigns combining antimalarial drugs and anti-infective vaccines as seasonal interventions for malaria control, elimination and prevention of resurgence: a modelling study"],"prefix":"10.1186","volume":"19","author":[{"given":"Flavia","family":"Camponovo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris F.","family":"Ockenhouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4972-593X","authenticated-orcid":false,"given":"Melissa A.","family":"Penny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,29]]},"reference":[{"key":"4467_CR1","unstructured":"World Health Organization (WHO). Global technical strategy for malaria 2016\u20132030. WHO Geneva. 2015. 1\u201335 p."},{"key":"4467_CR2","first-page":"1","volume":"2015","author":"S Bhatt","year":"2015","unstructured":"Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and. Nature. 2015;2015:1\u20139.","journal-title":"Nature."},{"key":"4467_CR3","unstructured":"World Health Organization (WHO). World Malaria Report. 2017:2017."},{"issue":"10","key":"4467_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.pt.2008.07.002","volume":"24","author":"BM Greenwood","year":"2008","unstructured":"Greenwood BM. Control to elimination: implications for malaria research. Trends Parasitol. 2008;24(10):449\u201354.","journal-title":"Trends Parasitol"},{"issue":"July","key":"4467_CR5","first-page":"1","volume":"44","author":"European Medicines Agency","year":"2015","unstructured":"European Medicines Agency. First malaria vaccine receives positive scientific opinion from EMA. Press Release. 2015;44(July):1\u20133.","journal-title":"Press Release"},{"key":"4467_CR6","unstructured":"Global Advisory Committee on Vaccine Safety. Safety monitoring of the RTS,S vaccine pilot implementation programme [Internet]. 2017 [cited 2017 Nov 1]. Available from: \n                    https:\/\/www.who.int\/vaccine_safety\/committee\/topics\/malaria_vaccine\/June_2017\/en\/"},{"key":"4467_CR7","doi-asserted-by":"crossref","unstructured":"Penny MA, Pemberton-Ross P, Smith TA. The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease. Malar J 2015;14(1):437.","DOI":"10.1186\/s12936-015-0969-8"},{"key":"4467_CR8","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","volume":"15","author":"MT White","year":"2015","unstructured":"White MT, Verity R, Griffi JT, Asante KP, Owusu-agyei S, Greenwood B, et al. Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine effi cacy : secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis. 2015;15:1450\u20138.","journal-title":"Lancet Infect Dis"},{"key":"4467_CR9","doi-asserted-by":"crossref","unstructured":"Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, Moon JE, et al. Fractional third and fourth dose of RTS,S\/AS01 malaria candidate vaccine: A phase 2a controlled human malaria parasite infection and immunogenicity study. J Infect Dis 2016;214(5):762\u2013771.","DOI":"10.1093\/infdis\/jiw237"},{"key":"4467_CR10","volume-title":"Sanaria\u00ae PfSPZ vaccine against malaria receives FDA fast track designation [internet]","author":"S Inc","year":"2016","unstructured":"Sanaria Inc. Sanaria\u00ae PfSPZ vaccine against malaria receives FDA fast track designation [internet]. 2016. Available from: \n                    http:\/\/www.sanaria.com"},{"issue":"6","key":"4467_CR11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nm.4110","volume":"22","author":"AS Ishizuka","year":"2016","unstructured":"Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016;22(6):614\u201323.","journal-title":"Nat Med"},{"issue":"March","key":"4467_CR12","first-page":"1","volume":"7","author":"KA Collins","year":"2017","unstructured":"Collins KA, Snaith R, Cottingham MG, Gilbert SC, Hill AVS. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci Rep. 2017;7(March):1\u201315.","journal-title":"Sci Rep"},{"key":"4467_CR13","doi-asserted-by":"crossref","unstructured":"Penny MA, Verity R, Bever CA, Sauboin C, Galactionova K, Flasche S, et al. Public health impact and cost-effectiveness of the RTS,S\/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet 2016;6736(15):1\u20139.","DOI":"10.1016\/S0140-6736(15)00725-4"},{"issue":"1","key":"4467_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12936-017-1841-9","volume":"16","author":"B Greenwood","year":"2017","unstructured":"Greenwood B, Dicko A, Sagara I, Zongo I, Tinto H, Cairns M, et al. Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine. Malar J. 2017;16(1):182.","journal-title":"Malar J"},{"key":"4467_CR15","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/ncomms1879","volume":"3","author":"M Cairns","year":"2012","unstructured":"Cairns M, Roca-Feltrer A, Garske T, Wilson AL, Diallo D, Milligan PJ, et al. Estimating the potential public health impact of seasonal malaria chemoprevention in African children. Nat Commun. 2012;3:881.","journal-title":"Nat Commun"},{"issue":"7","key":"4467_CR16","doi-asserted-by":"publisher","first-page":"e680","DOI":"10.1016\/S2214-109X(17)30220-6","volume":"5","author":"OJ Brady","year":"2017","unstructured":"Brady OJ, Slater HC, Pemberton-Ross P, Wenger E, Maude RJ, Ghani AC, et al. Role of mass drug administration in elimination of plasmodium falciparum malaria: a consensus modelling study. Lancet Glob Health. 2017;5(7):e680\u20137.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"4467_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-017-2010-x","volume":"16","author":"P Pemberton-Ross","year":"2017","unstructured":"Pemberton-Ross P, Chitnis N, Pothin E, Smith TA. A stochastic model for the probability of malaria extinction by mass drug administration. Malar J. 2017;16(1):1\u20139.","journal-title":"Malar J"},{"issue":"12","key":"4467_CR18","volume":"12","author":"E Poirot","year":"2013","unstructured":"Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J. Mass drug administration for malaria. Cochrane Database Syst Rev. 2013;12(12):CD008846.","journal-title":"Cochrane Database Syst Rev"},{"key":"4467_CR19","unstructured":"Zambia National Malaria Elimination Centre. National Malaria Elimination Strategic Plan 2017-2021 Moving from accelerated burden reduction to malaria elimination in Zambia 2017."},{"issue":"9","key":"4467_CR20","first-page":"1689","volume":"53","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Strategy for malaria elimination in the greater Mekong subregion (2015-2030). J Chem Inf Model. 2015;53(9):1689\u201399.","journal-title":"J Chem Inf Model"},{"key":"4467_CR21","unstructured":"Canavati S, Chea N, Guyant P, Roca-feltrer A, Yeung S. Strategy to Address Migrant and Mobile Populations for Malaria Elimination in Cambodia. National Center for Parasitology, Entomology and Malaria Control (CNM). Phnom Penh. 2013."},{"key":"4467_CR22","doi-asserted-by":"publisher","unstructured":"Penny MA, Maire N, Studer A, Schapira A, Smith TA. What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS ONE. 2008;3(9):e3193. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0003193\n                    \n                  .","DOI":"10.1371\/journal.pone.0003193"},{"key":"4467_CR23","unstructured":"OpenMalaria Microsimulation [Internet]. [cited 2016 Jul 1]. Available from: \n                    https:\/\/github.com\/SwissTPH\/openmalaria\/wiki"},{"issue":"Suppl 2","key":"4467_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4269\/ajtmh.2006.75.2_suppl.0750001","volume":"75","author":"T Smith","year":"2006","unstructured":"Smith T, Killeen GF, Maire N, Ross A, Molineaux L, Tediosi F, et al. Mathematical modeling of the impact of malaria vaccines on the Clinical epidemiology and natural history of plasmodium falciparum malaria : overview. Am J Trop Med Hyg. 2006;75(Suppl 2):1\u201310.","journal-title":"Am J Trop Med Hyg."},{"key":"4467_CR25","doi-asserted-by":"publisher","unstructured":"Smith T, Ross A, Maire N, Chitnis N, Studer A, Hardy D, et al. Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine. PLoS Med. 2012;9(1):e1001157. \n                    https:\/\/doi.org\/10.1371\/journal.pmed.1001157\n                    \n                  .","DOI":"10.1371\/journal.pmed.1001157"},{"issue":"5","key":"4467_CR26","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1007\/s11538-011-9710-0","volume":"74","author":"N Chitnis","year":"2012","unstructured":"Chitnis N, Hardy D, Smith T. A periodically-forced mathematical model for the seasonal dynamics of malaria in mosquitoes. Bull Math Biol. 2012;74(5):1098\u2013124.","journal-title":"Bull Math Biol"},{"issue":"Suppl 2","key":"4467_CR27","first-page":"11","volume":"75","author":"T Smith","year":"2006","unstructured":"Smith T, Maire N, Dietz K, Killeen GF, Vounatsou P, Molineaux L, et al. Relationship between the entomologic inoculation rate and the. Trop Med. 2006;75(Suppl 2):11\u20138.","journal-title":"Trop Med."},{"issue":"SUPPL. 2","key":"4467_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4269\/ajtmh.2006.75.19","volume":"75","author":"N Maire","year":"2006","unstructured":"Maire N, Smith T, Ross A, Owusu-Agyei S, Dietz K, Molineaux L. A model for natural immunity to asexual blood stages of plasmodium falciparum malaria in endemic areas. Am J Trop Med Hyg. 2006;75(SUPPL. 2):19\u201331.","journal-title":"Am J Trop Med Hyg"},{"issue":"Suppl 2","key":"4467_CR29","first-page":"32","volume":"75","author":"A Ross","year":"2006","unstructured":"Ross A, Killeen G, Smith T. Relationships between host infectivity to mosquitoes and asexual parasite density in. Trop Med. 2006;75(Suppl 2):32\u20137.","journal-title":"Trop Med."},{"issue":"2 Suppl","key":"4467_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4269\/ajtmh.2006.75.63","volume":"75","author":"A Ross","year":"2006","unstructured":"Ross A, Maire N, Molineaux L, Smith T. An epidemiologic model of severe morbidity and mortality caused by plasmodium falciparum. Am J Trop Med Hyg. 2006;75(2 Suppl):63\u201373.","journal-title":"Am J Trop Med Hyg."},{"issue":"Suppl 2","key":"4467_CR31","first-page":"56","volume":"75","author":"T Smith","year":"2006","unstructured":"Smith T, Ross A, Maire N, Rogier C, Molineaux L. An epidemiologic model of the incidence of acute illness in. Trop Med. 2006;75(Suppl 2):56\u201362.","journal-title":"Trop Med"},{"issue":"5","key":"4467_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0127818","volume":"10","author":"K Galactionova","year":"2015","unstructured":"Galactionova K, Tediosi F, De Savigny D, Smith T, Tanner M. Effective coverage and systems effectiveness for malaria case management in sub-Saharan African countries. PLoS One. 2015;10(5):1\u201321.","journal-title":"PLoS One"},{"issue":"9988","key":"4467_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTSS Clinical Trials Partnership","year":"2015","unstructured":"RTSS Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386(9988):31\u201345.","journal-title":"Lancet"},{"key":"4467_CR34","volume":"1","author":"B Zani","year":"2014","unstructured":"Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D. Dihydroartemisinin-piperaquine for treating uncomplicated plasmodium falciparum malaria. Cochrane Database Syst Rev. 2014;1:CD010927.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"4467_CR35","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/infdis\/jiw416","volume":"214","author":"TP Eisele","year":"2016","unstructured":"Eisele TP, Bennett A, Silumbe K, Finn TP, Chalwe V, Kamuliwo M, et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. J Infect Dis. 2016;214(12):1831\u20139.","journal-title":"J Infect Dis"},{"issue":"2","key":"4467_CR36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.mbs.2010.06.004","volume":"227","author":"PJ Dodd","year":"2010","unstructured":"Dodd PJ, White PJ, Garnett GP. Notions of synergy for combinations of interventions against infectious diseases in heterogeneously mixing populations. Math Biosci. 2010;227(2):94\u2013104.","journal-title":"Math Biosci"},{"issue":"4","key":"4467_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1001994","volume":"13","author":"R Gosling","year":"2016","unstructured":"Gosling R, von Seidlein L. The Future of the RTS,S\/AS01 Malaria Vaccine: An Alternative Development Plan. PLoS Med. 2016;13(4):1\u20136.","journal-title":"PLoS Med"},{"key":"4467_CR38","unstructured":"Glopbal Malaria Programme. WHO Malaria Policy Advisory Committee (MPAC) meeting. World Health Organisation; 2019 Apr."},{"key":"4467_CR39","unstructured":"Okell LC, Pemberton-Ross P, Wenger EA, Maude RJ, Brady OJ, Slater HC, et al. Consensus modelling evidence to support the design of mass drug administration programmes. World Health Organization. 2015."},{"issue":"6","key":"4467_CR40","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S1473-3099(17)30255-4","volume":"17","author":"A York","year":"2017","unstructured":"York A. Seasonal malaria chemoprevention in the Sahel. Lancet Infect Dis. 2017;17(6):588.","journal-title":"Lancet Infect Dis"},{"key":"4467_CR41","unstructured":"Isa\u00efe Medah. Proud to Protect Burkinab\u00e8 from Meningitis | | Blogs | CDC [Internet]. [cited 2019 Jul 17]. Available from: \n                    https:\/\/blogs.cdc.gov\/global\/2018\/04\/20\/proud-to-protect-burkinabe-from-meningitis\/"},{"key":"4467_CR42","unstructured":"Department of immunization vaccines and biologicals. Assessing the programmatic suitability of vaccine candidates for WHO prequalification [Internet]. World Health Organization; 2015 Jan [cited 2019 Jul 17]. Available from: \n                    https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/148168\/WHO_IVB_14.10_eng.pdf?sequence=1"},{"key":"4467_CR43","doi-asserted-by":"publisher","unstructured":"von Seidlein L, Hanboonkunupakarn B, Jittamala P, Pongsuwan P, Chotivanich K, Tarning J, Hoglund RM, Winterberg M, Mukaka M, Peerawaranun P, Sirithiranont P, Doran Z, Ockenhouse CF, Ivinson K, Lee C, Birkett AJ, Kaslow DC, Singhasivanon P, Day NPJ, Dondorp AM, White NJ, Pukrittayakamee S. Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S\/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers, Human Vaccines & Immunotherapeutics. 2019. \n                    https:\/\/doi.org\/10.1080\/21645515.2019.1643675\n                    \n                  .","DOI":"10.1080\/21645515.2019.1643675"},{"issue":"8","key":"4467_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0161311","volume":"11","author":"A Kuehne","year":"2016","unstructured":"Kuehne A, Tiffany A, Lasry E, Janssens M, Besse C, Okonta C, et al. Impact and lessons learned from mass drug administrations of malaria chemoprevention during the ebola outbreak in Monrovia, Liberia, 2014. PLoS One. 2016;11(8):1\u201317.","journal-title":"PLoS One"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4467-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4467-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4467-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:13:55Z","timestamp":1603844035000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4467-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,29]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4467"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4467-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,29]]},"assertion":[{"value":"1 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CFO and CL are part of the PATH\u2019s Malaria Vaccine Initiative.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"920"}}